Skip to main content
Premium Trial:

Request an Annual Quote

Caliper Cuts ’06 Outlook as SEC Review Delays Xenogen Acquisition

This article and headline have been updated from a previous version to clarify that Caliper lowered its outlook because of an SEC review of the Xenogen acquisition. 


NEW YORK, July 13 (GenomeWeb News) - Caliper Life Sciences lowered its previously announced financial outlook for the year due to an SEC review of the company's plan to buy Xenogen, which delayed the acquisition, the company said today.


Caliper revised its 2006 revenue forecast from between $120 million and $128 million to between $110 million and $118 million. A Caliper spokeswoman said that the US Securities and Exchange Commission selected the filing for review, which set the acquisition back by three months.


As GenomeWeb News reported in February, Caliper announced it would buy Xenogen for $80 million in stock and expected the transaction to close in the second quarter.


The delay required the company to adjust its projected revenues, which originally included Xenogen's second-quarter revenues, the spokeswoman said.  


The companies said they plan to hold a stockholder meeting on Aug. 9 to approve the acquisition.

The Scan

NFTs for Genome Sharing

Nature News writes that non-fungible tokens could be a way for people to profit from sharing genomic data.

Wastewater Warning System

Time magazine writes that cities and college campuses are monitoring sewage for SARS-CoV-2, an approach officials hope lasts beyond COVID-19.

Networks to Boost Surveillance

Scientific American writes that new organizations and networks aim to improve the ability of developing countries to conduct SARS-CoV-2 genomic surveillance.

Genome Biology Papers on Gastric Cancer Epimutations, BUTTERFLY, GUNC Tool

In Genome Biology this week: recurrent epigenetic mutations in gastric cancer, correction tool for unique molecular identifier-based assays, and more.